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Editor’s Farewell
For almost 10 years I have had the honor to be the
Editor-in-Chief of The American Journal of Pathology. This
issue is the last under my editorship. James Madara, the
new Editor-in-Chief, has in fact been on board since July,
handling new submissions. Beginning with the January
2001 issue, Jim and his team will take over all of the
editorial functions. This highly accomplished group will
make the journal even better in the coming years. I wish
Jim the very best and fully expect that he will be an
outstanding Editor-in-Chief of the AJP.
Not that long ago, there was a relatively limited number
of journals in the biomedical field, well recognized and
long standing. Today, of course, the scene is completely
different. Scientists and physicians are now confronted
with thousands of publications, many of them established
by commercial publishers without a clear mission or pur-
pose. Add to these the ever-increasing number of sub-
clones generated by the most prestigious journals and
the start of the electronic publishing era, which provides
exciting avenues for innovation but also anoints non-
peer-reviewed material and makes possible the prolifer-
ation of ghost journals. The present situation offers inter-
esting challenges, but is also fraught with pitfalls and
uncertainties. It is pleasing to see that the AJP not only
survives in these turbulent seas, but also thrives in them.
There is little dispute today that the AJP is the premier
journal in disease pathogenesis.
Originally titled The Journal of Medical Research, The
American Journal of Pathology will celebrate 100 years of
publication next year. The AJP not only has been able to
“go with the flow” to grow, but, more importantly, has
been at the forefront of scientific developments in pathol-
ogy. Research in the mechanisms of disease has gone
from morphology to molecular biology, passing through
physiology, ultrastructure, and cell biology. The best cur-
rent work, which the AJP has sought to publish, is not
based on a single technique, but uses instead a sophis-
ticated knowledge of morphology in conjunction with
powerful techniques of cell and molecular biology. I fear,
however, that in this time of rapid and spectacular scien-
tific advances and blurred distinctions between disci-
plines, the place of pathology and pathologists is not
assured. There is concern that pathology, which histori-
cally has been the basis for medicine, may be relegated
to a secondary role. In this worst-case scenario, the
cherished image of the pathologist as the guardian of
medical knowledge becomes transformed into that of a
specialized individual, highly skilled in an ancillary med-
ical procedure. (In the experimental realm, pathologists
might be confined to interpreting findings from transgenic
and knockout mice for molecular biologists, who often refer
to pathologists in rather quaint ways, eg, “my pathologist
tells me that this lymph node is not normal . . . .”) The
optimistic view is that what we are and what we want to
be are really up to us. If pathologists are to continue to be
major contributors to medical progress, we need to be
thoroughly familiar with scientific advances that now may
be perceived as being outside of pathology. This emerg-
ing scientific knowledge needs to be incorporated into
the education of pathologists as well as the practice of
pathology.
In my view, the brightest future for pathology in what
has been called the genomic or post-genomic era re-
quires a strong linkage between the science of patho-
genesis and diagnostic work. If the gap between these
traditional branches of pathology widens (a not uncom-
mon situation in many medical centers), I am afraid that a
great opportunity will have been missed. We have much
to contribute to medical knowledge and are in a unique
position to do it. But our role will not come to us by default.
Just the opposite is true: we must actively pursue it, so that
pathology is considered as both the science of pathogen-
esis, on an equal footing with other basic sciences, and a
diagnostic discipline that is complemented and strength-
ened by the new modalities of genomic analyses.
An indication of the vigorous pursuit of research in the
cellular and molecular biology of disease is that in ap-
proximately 9 years, manuscript submissions to the AJP
have increased from about 650 to more than 1,300 yearly.
The improvement in overall quality and importance of the
articles has also been noteworthy. Although we are the
“American” Journal of Pathology, more than 40% of sub-
missions and accepted papers originate from countries
other than the United States and Canada, attesting to the
universality of these endeavors. Interestingly, a cursory
survey of papers submitted during part of last year re-
vealed that only about 30% of the manuscripts originated
in departments, institutions, or centers with the word “pa-
thology” in their names. This may be interpreted in either
of two opposite ways. The reassuring interpretation is that
the science of pathogenesis is now pursued by a broad
spectrum of scientists regardless of affiliation. Indeed,
one of my original goals as Editor-in-Chief was to expand
the reach of The American Journal of Pathology to the
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scientific community at large, beyond the boundaries of
traditional pathology departments. However, the dark
and unfortunate side of this curious statistic is that, per-
haps because of a disconnect between research and
diagnosis in pathology departments or as an unintended
consequence of the newly expanded reach of research in
disease mechanisms, pathogenesis research as re-
flected by articles published in the AJP might be per-
ceived as not relevant to the practice of pathology. If this
is indeed the case, there is much work ahead for the new
AJP editorial team, which may need to redefine the AJP’s
intended audience.
My blueprint for the AJP was that it needed to be the
source for the best papers in cellular and molecular
mechanisms of disease—we wanted the best, not the
leftovers—and at the same time serve an educational
purpose by advancing the scientific frontiers of the dis-
cipline. To accomplish these goals, the editorial policies
had to be unbiased and fair and not controlled by a small
“in group.” At the same time, the AJP had to become fast
and efficient in its handling of manuscripts and publica-
tion time. My sense is that, by and large, the Journal did
meet these goals during the past 10 years. Credit for this
achievement goes to the Senior and Associate Editors, to
the Editorial Board members, and to the many reviewers
who graciously provided manuscript evaluations. In no
small part, the success of the journal is due to the superb
performance of Priscilla Markwood, the Managing Editor,
who was helped by a dedicated team of editorial assis-
tants in Bethesda and Seattle. I am delighted that we
have brought to the Editorial Board not only recognizable
“big names,” but also gifted scientists who may have
been less well known but who have outstanding records
in their young careers. They all have done an admirable
job. I also continue to be amazed and gratified by the
amount of time and care spent by the vast majority of our
reviewers in the evaluation of manuscripts. Though we
have also had a very small share of disappointments with
some reviews, I hope we have learned how to avoid most
of these experiences.
A journal that accepts only 25 to 30% of initial submis-
sions is bound to create unhappiness among some au-
thors. As an author myself, I certainly recognize both the
difficulty and the inevitability of the situation. All I can say
is that we have tried to be fair and unbiased, and have
relied on the evaluations of two reviewers and an Asso-
ciate Editor before making our final decision on a manu-
script. Undoubtedly, mistakes were made; I wish to be-
lieve that they were honest and unintentional.
The joys and excitement of being Editor-in-Chief of a
highly respected journal are, not too infrequently, tem-
pered by some troublesome events. Overlapping publi-
cations from a single laboratory (leading to a lack of
complete data in any single manuscript), the well known
MPU syndrome (that is, the splitting of data into minimal
publication units), the lack of appropriate disclosure of
conflicts of interest, the apparently deliberate failure to
acknowledge previous contributions by other laborato-
ries, are all common issues in journal publishing these
days. Needless to say, these unfortunate episodes ulti-
mately detract from the quality of the science and dimin-
ish the credibility of the author. Editors can help prevent
such problems, but the main responsibility lies with all of us
in our capacity as contributors to the scientific literature.
Regardless of the minor tribulations of the job, being
Editor-in-Chief of the Journal has been a privilege and an
unequaled learning experience. Similarly, my brief stint
as Editor-in-Chief of The Journal of Molecular Diagnostics,
the companion journal edited under the direction of
Karen Kaul, has been greatly rewarding. I wish to thank
all of you by paraphrasing the songwriter Woody Guthrie:
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